Last reviewed · How we verify
NCT05899270
3D-printed Reconstruction Automated Matching System Predicts Size of Double-lumen Tube: a Prospective Double-blinded Randomized Controlled Trial
NA trial testing 3D reconstruction automatic matching system in Lung Cancer in 200 participants. Status unknown.
30 November 2023
Quick facts
| Lead sponsor | Sichuan Cancer Hospital and Research Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 November 2023 |
| Primary completion | 30 November 2023 |
| Estimated completion | 30 March 2024 |
Drugs / interventions tested
- 3D reconstruction automatic matching system
- traditional method for selecting double lumen tube
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Lung Diseases — all drugs for Lung Diseases →
- Tracheal Intubation Morbidity — all drugs for Tracheal Intubation Morbidity →
- Throat Injury — all drugs for Throat Injury →
Sponsor
Sichuan Cancer Hospital and Research Institute
Who can join
Adults 18 to 75, any sex, with Lung Cancer or Lung Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung isolation techniques are commonly used to facilitate surgical exposure and to provide single-lung ventilation for patients. We have developed an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.The aim of this study was to compare whether the use of 3DRACS to select a DLT size compared to conventional empirical selection methods could improve incidence of DLT intubation success and reduce airway injury.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05899270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Sichuan Cancer Hospital and Research Institute trials
Trials by the same sponsor.
- NCT07269912 — Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer · not yet recruiting
- NCT07082699 — The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of · NA · not yet recruiting
- NCT06939764 — Application of the sG8 Scale in Real-World Geriatric Oncology Patients · not yet recruiting
- NCT06717854 — Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial · NA · not yet recruiting
- NCT06860685 — Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05899270 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Cancer Hospital and Research Institute
- Last refreshed: 12 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing